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In this study, we measured the insulin-like growth factor 
(IGF)-I levels and evaluated the serum protein profiles of 
diabetic, insulin-treated, and healthy cats and dogs. The 
total  IGF-I  concentrations  were  33.74  ±  3.4  ng/mL  for 
normal, 25.8 ±  4.5 ng/mL for diabetic, and 180.4 ±  31.4 
ng/mL for insulin-treated cats. IGF-I concentrations were 
46.4 ± 6.6 ng/mL for normal, 25.1 ± 4.1 ng/mL for diabetic, 
and  303.0  ±  61.3  ng/mL  for  insulin-treated  dogs.  Total 
serum  protein  profiles  were  analyzed  by  SDS-PAGE. 
Fourteen bands ranging from 25 to 240 kDa in size were 
observed for cats, and 17 bands ranging from 25 to 289 kDa 
were observed for dogs. The densities of the bands differed 
among  control,  diabetic,  and  insulin-treated  animals.  In 
conclusion, we found that serum protein profiles and IGF-I 
concentrations  were  altered  in  both  diabetic  and 
insulin-treated animals. When judiciously interpreted in the 
light of other clinical and laboratory data, the techniques 
used in our study provide a valuable modality for measuring 
the severity of diabetes mellitus in dogs and cats.
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Introduction
Diabetes mellitus is one of the most common metabolic 
diseases in cats and dogs. This condition is characterized 
by increased levels of blood glucose (hyperglycemia) 
resulting from defects in insulin secretion, insulin action, 
or both [2,16]. It causes disorders in the metabolism of 
carbohydrates, lipids, and protein [29]. Diabetes mellitus is 
classified into four types; in humans, the most common are 
insulin dependent (type 1) and non-insulin dependent (type 
2). 
Type 1 diabetes is characterized by insulin secretion 
deficiencies and is treated with insulin injections in both 
dogs and humans. In cases of type 2 diabetes, insulin is 
secreted but glucose metabolism is inhibited due to insulin 
resistance. In humans and felines, this form of diabetes is 
characterized by amyloid deposition in Langerhans 
islands. Among animals, the prevalence of the different 
forms of diabetes varies with species. While type 1 
diabetes is usually seen in dogs, type 2 more frequently 
develops in cats [30,31,47]. Other types of diabetes 
account for a smaller ratio of cases in dogs and cats. Insulin 
was first described by Banting and Best in 1921 [5] as a 
factor responsible for glucose homeostasis. This hormone 
facilitates glucose entrance into the cell. Its deficiency 
leads to increased protein catabolism [41,44] and 
hyperglycemia. Insulin is an anabolic agent and an 
important regulator of the growth hormone (GH) and 
insulin-like growth factors (IGF) [7].
The two major IGF-I and -II were found to be low 
molecular weight polypeptide hormones [34]. IGF-I is 
mainly synthesized in the liver, and the secretion of IGF-I 
was stimulated by growth hormone [38]. This polypeptide 
shares many structural, functional, and metabolic similarities 
with insulin and proinsulin [34]. Most circulating IGF-I is 
bound to specific carrier proteins; only free IGF-I is 
biologically active. Six IGF-binding proteins (IGFBP) 
have been identified (IGFBP-1 to IGFBP-6), four of which 
are important in human serum (IGFBP-1 to IGFBP-4). 
IGFBP-3 is the major binding protein for IGF-I that forms 
a 140 kDa complex in humans, and plays a role in glucose 
metabolism [23]. The active form of IGF-I binds to the 
IGF-I receptor, which is highly homologous to the insulin 
receptor, and activates a cascade of intracellular events that 
result in the stimulation of glucose utilization [19,27].
The effects of IGF-I have been investigated in several 
experimental animal studies [10,37]. IGF-I has been 
reported to have effects similar to those of insulin such as 
increasing glucose uptake, stimulation of glucose 
transport, glucose oxidation, and glycogen formation. 
IGF-I is also known to have anabolic effects on protein 
metabolism, including inhibition of whole-body protein 
breakdown and stimulation of protein synthesis [17]. In 326    Gulay Ciftci et al.
humans with untreated cases of type 1 or 2 diabetes, the 
levels of IGF-I have been reported to decrease [3,19]. 
IGFBP-3 concentrations have also been found to decrease 
in hyperglycemic humans [6] and rats [13,18]. The aim of 
the present study was to compare IGF-I levels between 
healthy, insulin-treated diabetic, and hyperglycemic cats 
and dogs. In addition, we evaluated the serum protein 
profiles of these animals.
Materials and Methods
Samples
Seven cats (6 striped and 1 Turkish angora) with diabetes 
mellitus and seven cats (4 striped, 2 Turkish angora and 1 
Scottish fold) with insulin-treated were used for study. 
Twenty dogs (13 mongrel, 5 wolfhound, 1 Huskey and 1 
Turkish kangal) with diabetes mellitus and seven dogs (4 
mongrel and 3 wolfhound) with insulin-treated mellitus 
were also included in our study. The animals used in the 
study were selected from the animals which were come to 
the polyclinics for routine health controls or diabetes 
treatment. Finally, seven healthy cats (5 striped, 1 Turkish 
angora and 1 Turkish van) and seven healthy dogs (3 
mongrel, 2 wolfhound, and 2 Turkish kangal) served as 
control groups. The age of all animals ranged from 4 to 16 
years (median, 10 years) and average body weights ranged 
from 2.5 to 9.8 kg (median, 5.5 kg). The diagnosis of 
diabetes mellitus was determined based on clinical signs 
such as polyuria, polydipsia, and weight loss, and 
laboratory findings indicating the presence of 
hyperglycemia and glucosuria.
Biochemical analysis of serum
The neutral protamine Hagedorn form of insulin 
(Humulin-N; Eli Lilly, USA) was subcutaneously injected 
at a concentration of 0.4∼0.7 IU/kg for dogs and 0.25∼
0.5 IU/kg for cats with insulin-treated diabetes. Blood 
samples were collected 1.5 h after insulin injection from 
cats and dogs fasted for approximately 8 h. The samples 
were kept at room temperature for 15 min to allow clotting 
and were then centrifuged (4
oC, 1,550 × g, 10 min). The 
sera recovered from the samples were stored at 򰠏80
oC until 
use. The levels of glucose, total protein, albumin, and 
globulin were determined using a bench-top immunoassay 
auto-analyzer (Autolab; AMS Srl, The Netherlands).
Detection of insulin-like growth factor (IGF) I in 
serum
The concentration of IGF-I in the serum samples was 
analyzed by using a sandwich enzyme-linked immunoassay 
(ELISA) kit (E90050Ca; Uscn Life Science, China). The 
ELISA was performed according to manufacturer’s 
instructions as follows; the wells of precoated kits were 
determined for diluted standards, blank and samples. Each 
of dilutions of standards, blank and samples were added 
about 100 μL to the wells and incubated for 2 h at 37
oC. 
After washing step, 100 μL of Detection Reagent A 
working solution was added to each well and incubated for 
1 h at 37
oC. The wells were washed and 100 μL of 
Detection Reagent B working solution was added to each 
well. After incubation for 30 min at 37
oC, the washing 
process was repeated. TMB Substrate Solution (90 μL to 
each well) was added and incubated for 15∼25 min at 
37
oC. Then, 50 μL of Stop Solution was added to each well 
and measurement was conducted at 450 nm.
Sodium  dodecyl  sulphate-polyacrylamide  gel 
electrophoresis  (SDS-PAGE)  analysis  of  serum 
proteins
SDS-PAGE was carried out on 10% polyacrylamide gels 
under denaturing conditions [20]. Serum samples were 
diluted (v/v; 1/50) with a sterile physiologic saline 
solution, mixed with 15.5 mmol/L Tris-HCl, 3% SDS, 
10% glycerol and 0.02% bromophenol blue (pH 6.8); and 
heated at 100
oC for 5 min followed by gentle cooling. 
Samples (20 μL) were loaded onto the stacking gel and 
electrophoresis was performed at a constant voltage (200 
V). Following electrophoresis, the gel was stained with 
Blue Silver [12]. Molecular mass standards (S8445; 
Sigma, USA) were run in parallel in order to calculate 
protein molecular weights using Molecular Imaging 
Software (Kodak, USA). The SDS-PAGE results were 
evaluated for variation of band densities as well as 
similarities in the number and patterns of the bands. 
Dendograms (UPGMA) were created based on the Dice 
similarity coefficient including the genetic relatedness 
between groups (cats and dogs; control and diabetic cats; 
control and diabetic dogs; insulin-treated cats and dogs) 
using CHEF-DR III and Quantity One Software (Bio-Rad 
Laboratories, USA).
Statistical analysis
Normal distribution of the data was determined with the 
Shapiro-Wilk test and while general distribution parameters 
of data were evaluated with descriptive statistics. To 
investigate statistical differences among the IGF-I, 
albumin, globulin, and total protein concentrations 
between the groups in this study, we initially performed 
Duncan’s multiple range test. Pearson Correlations 
Analysis was also used to evaluate the relationships among 
the traits we examined in the present study. Statistical 
analyses were performed with SAS, statistical package 
release 8.1 (SAS, USA).
Results
The concentrations of IGF-I were 25.8 ± 4.50 g/mL and 
25.1 ± 4.10 ng/mL in diabetic cats and dogs, respectively. IGF-I and serum protein profile of diabetic cats and dogs    327
Table 4. Correlation between serum parameters in dogs
Glucose IGF-I Albumin Total protein Globulin
Glucose 1.000 򰠏0.326 0.009 򰠏0.123 򰠏0.105
IGF-I 򰠏0.326 1.000 0.386 0.129 򰠏0.068
Albumin 0.009 0.190 1.000 0.236 򰠏0.534
Total protein 򰠏0.123 0.129 0.236 1.000 0.687
Globulin 򰠏0.105 򰠏0.068 򰠏0.534 0.687 1.000
Table 1. Results of biochemical tests for control, diabetic, and insulin-treated cats
Parameter Control Diabetic Insulin-treated F-value
IGF-I (ng/mL) 33.7 ± 3.4
a 25.8 ± 4.5
a 180.4 ± 31.4
b 22.2
Glucose (mg/dL) 58 ± 18.8
a 255 ± 52.5
b 102.4 ± 5.5
a 10.6
Total protein (g/dL) 6.8 ± 0.1
a 6.6 ± 0.1
a 　　6.6 ± 0.1
a 　0.2
Albumin (g/dL) 3.1 ± 0.09
a 2.4 ± 0.1
b 　　3.1 ± 0.1
a 　8.1
Globulin (g/dL) 3.6 ± 0.07
a 4.2 ± 0.1
b 　　3.5 ± 0.1
a 　5.7
a,bDifferent superscripts in the same row indicate significant differences (p < 0.05). IGF: insulin-like growth factor.
Table 2. Results of biochemical tests for control, diabetic, and insulin-treated dogs
Parameter Control Diabetic Insulin-treated F-value
IGF-I (ng/mL) 46.4 ± 6.6
a 25.1 ± 4.1
a 303 ± 61.3
b 49.5
Glucose (mg/dL) 89 ± 2.6
a 304.1 ± 27.4
b 106.7 ± 7.7
a 0.5
Total protein (g/dL) 6.8 ± 0.08
a 6.5 ± 0.07
a 6.7 ± 0.1
a 1.6
Albumin (g/dL) 2.7 ± 0.08
a 2.9 ± 0.06
a 2.9 ± 0.1
a 2.6
Globulin (g/dL) 4.1 ± 0.1
a 3.6 ± 0.08
a 3.7 ± 0.2
a 13.5
a,bDifferent superscripts in the same row indicate significant differences (p < 0.05).
Table 3. Correlation between serum parameters in cats
Glucose IGF-I Albumin Total protein Globulin
Glucose 1.000 򰠏0.232 򰠏0.633 0.058 0.656
IGF-I 򰠏0.232 1.000 0.386 0.116 򰠏0.232
Albumin 򰠏0.633 0.386 1.000 0.322 򰠏0.751
Total protein 0.058 0.116 0.322 1.000 0.331
Globulin 0.656 򰠏0.232 򰠏0.751 0.331 1.000
These levels were significantly lower than those of the 
control groups (33.7 ± 3.40 ng/mL and 46.4 ± 6.60 ng/mL 
for control cats and dogs, respectively). The IGF-I 
concentrations for insulin-treated cats and dogs were 180.4 
± 31.40 ng/mL and 303.0 ± 61.30 ng/mL, respectively. 
These results showed that the concentration of IGF-I in 
sera of diabetic cats and dogs were significantly lower than 
those of both healthy and insulin-treated animals (p < 
0.05). IGF-I concentrations increased significantly with 
insulin treatment in diabetic animals. The importance 
control of differences among the groups’ means with 
Duncan’s multiple range test are shown in Tables 1 and 2.
There was a negative correlation between the serum 
albumin and globulin concentration in cats (r = 򰠏0.751) and 
dogs (r = 򰠏0.534). A positive correlation (r = 0.656) 
between serum glucose and globulin concentrations was 
found in cats. A positive correlation was also observed 
between total protein and globulin (r = 0.687) levels. The 328    Gulay Ciftci et al.
Fig. 1. (A) SDS-PAGE analysis and (B) dendogram analysis (phylophenotic tree created according to the SDS-PAGE profiles) of the
representative serum from control, insulin-treated, diabetic dogs and cats. Lane 1: control cats, Lane 2: diabetic cats, Lane 3: 
insulin-treated cats, Lane 4: control dogs, Lane 5: diabetic dogs, Lane 6: insulin-treated dogs, Lane M: marker.
correlation between some serum parameters of cats and 
dogs are presented in Tables 3 and 4, respectively.
In the SDS-PAGE analysis of total serum proteins of all 
cats and dogs, 14 bands between 25 to 240 kDa in size and 
17 bands between 25 to 289 kDa were observed. The 
density of the bands which were approximately 29, 34, 42, 
44, and 240 kDa in size were different between control, 
diabetic, and insulin-treated animals (Fig. 1). The 
similarities of the sizes of protein bands were evaluated 
with software as described above. Serum profiles were 
found to have a similarity of 72% between cats and dogs, 
75% between control and diabetic cats, 79% between 
control and diabetic dogs, 83% between diabetic and 
insulin-treated cats, and 93% between diabetic and 
insulin-treated dogs.
Discussion
Diabetes is a very complex disease and differences in 
some serum parameters between diabetic cats and dogs are 
still unclear. IGF-I is a hormone which resembles insulin in 
terms of molecular structure and biochemical properties. 
Recent study has suggested that IGF-I plays a role in 
regulating glucose metabolism [39]. The results of the 
present study confirmed that diabetes in cats and dogs 
adversely affected serum IGF-I concentration. We 
measured serum concentrations of IGF-I in diabetic cats 
and dogs that had been previously treated with insulin as 
well as untreated animals. The serum IGF-I concentrations 
in untreated diabetic cats and dogs were significantly lower 
than those of the control cats and dogs. However, the serum 
IGF-I concentrations in the insulin-treated diabetic cats 
and dogs were higher than those in healthy as well as 
untreated diabetic animals. Several studies [7,15,33,38,42] 
have also measured serum IGF-I concentrations in diabetic 
cats and dogs; these concentrations were reduced in these 
animals. Similarly, IGF-I concentrations were also 
reported to be decreased in type 1 and type 2 diabetic 
humans [4,11,14] and rats [1,38].
Insulin and sex steroids have stimulatory effects on the 
synthesis and secretion of IGF-I [9]. The major source of 
circulating IGF-1 is produced by the liver and is dependent 
on appropriate insulin levels [41]. Low levels of insulin 
secretion over a long time result in reduced IGF-I 
secretion. Although the structure, function, and regulation 
of IGF-I in humans, rodents, and non-human primates have 
been reported, few studies about IGF-I in diabetic cats and 
dogs exist in the literature [43]. It has been found that the 
reduction of circulating IGF-I causes decreases in insulin 
levels [40], increased protein synthesis, and inhibited 
protein catabolism [36]. The levels of IGF-I have been 
reported to be high in diabetic and acromegalic cats and 
dogs [8,15]. However, no changes was found in diabetes 
mellitus for IGF-I concentrations [18]. Albumin constitutes 
a large proportion of all plasma protein [46]. In 
hyperglycemia, serum albumin levels have been reported 
to decrease [26] while the urinary excretion of albumin has 
been reported to increase with diabetes [45]. In the present 
study, the total protein, globulin, and albumin concentrations 
of all dogs were not significantly different. The levels of 
albumin in diabetic cats were lower than those of the 
insulin-treated diabetic and control cats. However, an 
increase in serum globulin concentrations was observed in 
diabetic cats. Globulins constitute a much smaller fraction 
of the total serum protein content. The increased levels of 
globulin in our study might have been due to increased β-1 
or β-2 globulins reported to occur with diabetes mellitus 
[28]. We also noted a statistically significant increase in the IGF-I and serum protein profile of diabetic cats and dogs    329
serum glucose concentration of diabetic cats and dogs (p < 
0.001).
Serum protein profiling provides a valuable tool for 
diagnosing many diseases [21,29]. In the serum SDS- 
PAGE analysis performed in this study, we identified 14 
bands ranging from 25 to 240 kDa in size in cats, and 17 
bands between 25 in size 289 kDa in dogs. The intensities 
of the 25, 29, 34, 32, 42, 44, and 240 kDa bands were 
different when comparing control, diabetic, and insulin- 
treated dogs and cats. Most circulating IGF-I is bound to 
specific proteins; only free IGF-I is biologically active. So 
far, six different IGFBP isoforms with molecular weights 
ranging between 25∼150 kDa have been found [35]. Four 
of these are important in human serum (IGFBP-1 to 4) in 
which IGF-I is predominantly bound to IGFBP-3 [32]. On 
the other hand, a previous study [25] reported that 
IGFBP-3 appears as doublet (39 and 43 kDa) in cats. 
Lewitt et al. [22] has also reported that cat serum contains 
IGFBP-3 doublets bands with molecular masses of 
approximately 45 kDa and 25∼35 kDa. We observed 
doublet bands with molecular masses of 42∼44 kDa and 
32∼34 kDa in cats and dogs, respectively. The intensities 
of the 32, 34, 42, and 44 kDa bands in diabetic cats were 
found to be lower than those of insulin-treated and control 
cats. On the other hand, the intensities of 32, 34, 42, and 44 
kDa bands in diabetic dogs were higher than those of 
insulin-treated dogs.
A 29 kDa band has been previously identified as IGFBP-1 
in cats by immunoblotting [25]. In our study, the density of 
29 kDa protein band was found as decreased in 
insulin-treated cats whereas the density of 25 kDa protein 
band increased in diabetic compared to insulin-treated 
cats. However, an increase in the densities of the 29 and 25 
kDa protein bands was observed in insulin-treated dogs. In 
diabetic cats and dogs, the density of 240 kDa band 
decreased; however, the density of this band increased 
after insulin treatment. In summary, the densities of the 
240, 42, 44, 32, 34, and 25 kDa bands increased but the 29 
kDa band decreased in insulin-treated cats. In 
insulin-treated dogs, the 240, 49, 29, and 25 kDa band 
densities increased but the density of the 42 and 44 kDa 
bands decreased. These results indicate that the protein 
factors corresponding to the 240, 44, 42, 25, and 29 kDa 
bands may have important effects on glucose homoeostasis 
in both cats and dogs.
SDS-PAGE band patterns have been increasingly used to 
determine the relationships or similarities between two 
groups (cats and dogs; control and diabetic cats; control 
and diabetic dogs; insulin-treated cats and dogs). 
Computerized comparison of electrophoretic protein 
patterns is a fast, easy, and powerful analytical method. 
SDS-PAGE patterns can be quickly obtained, are 
reproducible, and do not require any relatively 
sophisticated and expensive reagents or equipment [24]. 
No comparison of serum protein profiles among cats and 
dogs (diabetic, insulin-treated, and control) has been 
reported in the literature. Our SDS-PAGE analysis 
demonstrated that the serum profiles between the different 
groups of animals were generally similar (72 to 93%).
In conclusion, the findings obtained in this study 
suggested that variations of serum protein profiles and 
IGF-I concentrations in cats and dogs with diabetic or 
insulin-treated may be associated with glucose metabolism. 
Serum protein profiles, when supported by other clinical 
and laboratory data, are a valuable additional way to 
measure the severity of diabetes. However, further studies 
are required for fully understanding the mechanisms 
underlying this disease.
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